Anti-Ro/SSA Antibodies Blocking Calcium Channels As a Potentially Reversible Cause of Atrioventricular Block in Adults
Overview
Authors
Affiliations
Background: In ∼50% of severe atrioventricular blocks (AVBs) occurring in adults <50 years, the underlying etiology remains unknown. Preliminary evidence from case reports suggests that autoimmunity, specifically the presence of circulating anti-Ro/SSA antibodies in the patient (acquired form), in the patient's mother (late-progressive congenital form), or in both (mixed form), could be involved in a fraction of idiopathic AVBs in adults by possibly targeting the L-type calcium channel (Ca1.2) and inhibiting the related current (I).
Objectives: The purpose of this study was to evaluate whether anti-Ro/SSA antibodies are causally implicated in the development of isolated AVBs in adults.
Methods: Thirty-four consecutive patients with isolated AVB of unknown origin and 17 available mothers were prospectively enrolled in a cross-sectional study. Anti-Ro/SSA antibodies were assessed by fluoroenzyme-immunoassay, immuno-Western blotting, and line-blot immunoassay. Purified immunoglobulin-G (IgG) from anti-Ro/SSA-positive and anti-Ro/SSA-negative subjects were tested on I and Ca1.2 expression using tSA201 and HEK293 cells, respectively. Moreover, in 13 AVB patients, the impact of a short course of steroid therapy on AV conduction was evaluated.
Results: Anti-Ro/SSA antibodies, particularly anti-Ro/SSA-52kD, were found in 53% of AVB-patients and/or in their mothers, most commonly an acquired or mixed form (two-thirds of cases) without history of autoimmune diseases. Purified IgG from anti-Ro/SSA-positive but not anti-Ro/SSA-negative AVB patients acutely inhibited I and chronically down-regulated Ca1.2 expression. Moreover, anti-Ro/SSA-positive sera showed high reactivity with peptides corresponding to the Ca1.2 channel pore-forming region. Finally, steroid therapy rapidly improved AV conduction in AVB-patients with circulating anti-Ro/SSA antibodies but not in those without.
Conclusions: Our study points to anti-Ro/SSA antibodies as a novel, epidemiologically relevant and potentially reversible cause of isolated AVB in adults, via an autoimmune-mediated functional interference with the L-type calcium channels. These findings have significant impact on antiarrhythmic therapies by avoiding or delaying pacemaker implantation.
Nicola S, Borrelli R, Corradi F, Lo Sardo L, Badiu I, Romito A Front Immunol. 2024; 15:1390642.
PMID: 39221240 PMC: 11361985. DOI: 10.3389/fimmu.2024.1390642.
Gonano N, Nuzzi V, Pavan D, Piazza R, Pecoraro R, Altinier A ESC Heart Fail. 2024; 11(6):4407-4412.
PMID: 39001591 PMC: 11631281. DOI: 10.1002/ehf2.14822.
Gamazo-Herrero J, Medina-Luezas J, Cusacovich I, Martin-Asenjo M, Gonzalez-Montagut-Gomez C, Sanchez-Gonzalez M J Clin Med. 2024; 13(12).
PMID: 38930039 PMC: 11204400. DOI: 10.3390/jcm13123510.
Li T, Marashly Q, Kim J, Li N, Chelu M Expert Opin Ther Targets. 2024; 28(5):385-400.
PMID: 38700451 PMC: 11395937. DOI: 10.1080/14728222.2024.2351501.
Huang Y, Deng J, Liu J, Yang F, He Y Arthritis Res Ther. 2024; 26(1):8.
PMID: 38167489 PMC: 10759413. DOI: 10.1186/s13075-023-03246-w.